Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study
Abstract Background Severe asthma (SA) is a heterogeneous disease composed of various clinical phenotypes, and criteria for selecting the most appropriate biological agent remain unclear. Therefore, when optimal control cannot be achieved with the initial biological therapy, switching between biolog...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-11-01
|
| Col·lecció: | BMC Pulmonary Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12890-025-04044-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|